• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

TG Therapeutics Prices Briumvi at the Lowest for Any Branded MS Therapy, but ICER Says That’s Not Low Enough


The newly approved treatment for relapsing multiple sclerosis is priced at $59,000 per year. The Institute for Clinical and Economic Review said it should be priced at between $16,000 and $34,900 to meet commonly accepted thresholds for cost effectiveness.

TG Therapeutics’ Briumvi (ublituximab) was approved by the FDA at the end of December 2022 for the treatment of relapsing forms of multiple sclerosis (MS). In January, it became commercially available.

Briumvi joins Genentech’s Ocrevus (ocrelizumab) and Novartis’ Kesimpta (ofatumumab) as the third anti-CD20 monoclonal antibody approved to treat relapsing MS. According to TG Therapeutics, Briumvi is more potent than other therapies in its class, which allows for a shorter infusion time than Ocrevus (1 hour versus 2 to 3.5 hours). Kesimpta is dosed as a subcutaneous injection.

Recently, TG Therapeutics announced that it plans to make Briumvi the most accessible therapy in its class by pricing it at $59,000 per year. This is the lowest price of any brand-name therapy currently approved to treat MS.

Even so, based on this year’s Final Evidence Report from the Institute for Clinical and Economic Review (ICER), this price is not low enough. In a panel vote, ICER found no net health benefit of Briumvi compared with other monoclonal antibodies prescribed to treat relapsing forms of MS. The list included Rituxan (rituximab), which is not currently FDA-approved to treat MS but is used off-label. The panelists found adequate clinical evidence showing a net health benefit of Briumvi over certain oral treatments, including fumarates and Novartis’ Gilenya (fingolimod).

However, ICER calculates that Briumvi, along with other monoclonal antibodies that treat MS, would have to be priced between $16,500 and $34,900 per year to achieve common thresholds for cost-effectiveness. For TG Therapeutics, this would mean discounting the treatment by at least 59% of its current price.

Currently, the company offers a patient support program to help patients in the United States gain access to Briumvi. For patients with commercial insurance, the program assists with copays. Patients without insurance coverage or those who are covered by government-funded programs, such as Medicaid or Medicare, may be able to obtain the treatment free of charge if they meet certain financial qualifications.

Related Content
© 2024 MJH Life Sciences

All rights reserved.